On the other hand, a recent study found that circulating Gzmb+CD8+T cells and Gzmb+CD19+ B cells were significantly increased in MS patients during fingolimod and natalizumab treatments (35), suggesting that B cells may exhibit cytotoxic behavior similar to CD8+ T lymphocytes in MS patients under different treatments. This evidence concerns the gene CD19 and myeloid sarcoma.